**2-(4-Benzofuro[3,2-d]pyrimidinylthio)-1-thiophen-2-ylethanone** is a chemical compound that has shown promising activity as a **kinase inhibitor**.
Here's a breakdown of its structure and importance in research:
* **Structure:** The compound is a complex organic molecule containing a benzofuro[3,2-d]pyrimidine ring system attached to a thiophene ring via a sulfur atom. This specific arrangement of atoms gives it unique properties.
* **Kinase Inhibition:** Kinases are enzymes that play crucial roles in cell signaling pathways, regulating cell growth, differentiation, and survival.
* Many diseases, including cancer and inflammatory conditions, are driven by abnormal kinase activity.
* Compounds that inhibit specific kinases are therefore potential therapeutic agents.
* **Research Significance:** 2-(4-Benzofuro[3,2-d]pyrimidinylthio)-1-thiophen-2-ylethanone has been studied for its potential to inhibit specific kinases, particularly those involved in:
* **Cancer:** The compound has shown activity against certain cancer cell lines, suggesting it could be a potential anticancer drug.
* **Inflammation:** Some kinases play a role in inflammatory responses. Inhibition of these kinases could be beneficial in treating inflammatory conditions.
**Important Notes:**
* **Early Stage Research:** While promising, 2-(4-Benzofuro[3,2-d]pyrimidinylthio)-1-thiophen-2-ylethanone is still in the early stages of research. Further studies are needed to:
* **Determine its efficacy and safety in humans.**
* **Identify the specific kinases it targets.**
* **Develop drug formulations and delivery methods.**
* **Other Potential Applications:** The compound's unique structure and biological activity may also make it relevant in other areas of research, such as:
* **Agricultural chemistry:** Inhibition of specific kinases in plants could lead to improved crop yields or pest control.
* **Material science:** The compound's properties could be useful in designing new materials with specific functions.
**In summary, 2-(4-Benzofuro[3,2-d]pyrimidinylthio)-1-thiophen-2-ylethanone is a promising lead compound for the development of new kinase inhibitors with potential therapeutic applications in cancer, inflammation, and other areas.**
ID Source | ID |
---|---|
PubMed CID | 664458 |
CHEMBL ID | 1347130 |
CHEBI ID | 121327 |
Synonym |
---|
2-([1]benzofuro[3,2-d]pyrimidin-4-ylsulfanyl)-1-(thiophen-2-yl)ethanone |
STL345179 |
UPCMLD0ENAT5791973:001 |
smr000045449 |
MLS000040696 , |
CHEBI:121327 |
2-([1]benzofuro[3,2-d]pyrimidin-4-ylsulfanyl)-1-thiophen-2-ylethanone |
AKOS001366972 |
HMS2178D23 |
CHEMBL1347130 |
2-(4-benzofuro[3,2-d]pyrimidinylthio)-1-thiophen-2-ylethanone |
2-(benzofuro[3,2-d]pyrimidin-4-ylthio)-1-(2-thienyl)ethanone |
bdbm47062 |
2-([1]benzofuro[3,2-d]pyrimidin-4-ylsulfanyl)-1-thiophen-2-yl-ethanone |
cid_664458 |
Z82167278 |
Q27209863 |
Class | Description |
---|---|
benzofurans | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 1.9012 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
Nrf2 | Homo sapiens (human) | Potency | 3.4720 | 0.0920 | 8.2222 | 23.1093 | AID624171; AID651593; AID651597 |
chaperonin-containing TCP-1 beta subunit homolog | Homo sapiens (human) | Potency | 1,258.9301 | 3.9811 | 27.7649 | 39.8107 | AID504842 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 6.4052 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 2.8184 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 3.2643 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 3.9811 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 3.5481 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
relaxin receptor 1 isoform 1 | Homo sapiens (human) | Potency | 22.3872 | 0.0388 | 14.3501 | 43.6206 | AID2676 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 31.6228 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 16.2710 | 1.0000 | 10.4756 | 28.1838 | AID1457; AID901 |
CREB-binding protein | Homo sapiens (human) | Potency | 4.6011 | 0.0282 | 2.3600 | 12.5893 | AID907; AID916 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
photoreceptor-specific nuclear receptor | Homo sapiens (human) | IC50 (µMol) | 39.8410 | 0.0374 | 2.9340 | 8.9620 | AID2758 |
nuclear receptor corepressor 2 isoform 2 | Homo sapiens (human) | IC50 (µMol) | 15.2940 | 1.0250 | 4.3611 | 9.9550 | AID2759 |
peroxisome proliferator-activated receptor gamma isoform 2 | Homo sapiens (human) | IC50 (µMol) | 15.2940 | 1.0250 | 4.3611 | 9.9550 | AID2759 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
cytoplasm | CREB-binding protein | Homo sapiens (human) |
nucleus | CREB-binding protein | Homo sapiens (human) |
nucleoplasm | CREB-binding protein | Homo sapiens (human) |
cytoplasm | CREB-binding protein | Homo sapiens (human) |
cytosol | CREB-binding protein | Homo sapiens (human) |
nuclear body | CREB-binding protein | Homo sapiens (human) |
chromatin | CREB-binding protein | Homo sapiens (human) |
histone acetyltransferase complex | CREB-binding protein | Homo sapiens (human) |
transcription regulator complex | CREB-binding protein | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504787 | Counterscreen for agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3): TR-FRET-based biochemical high throughput assay to identify agonists of the interaction between peroxisome proliferator-activated receptor gamma (PPARg) and nuclear rec | 2006 | Assay and drug development technologies, Jun, Volume: 4, Issue:3 | Development of the high throughput screening assay for identification of agonists of an orphan nuclear receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.41) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |